🇺🇸 FDA
Patent

US 9526777

Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein

granted A61KA61K2039/5254A61K2039/5256

Quick answer

US patent 9526777 (Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Dec 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K2039/5254, A61K2039/5256, A61K2039/545, A61K39/12